Year: 2003
Type: article
Abstract: A neurologist once told me that he found the subject of rating scales ''exceedingly dull'', while another found the area ''abstruse''.I have therefore attempted to produce an overview that is helpful and conveys some of the basic principals underlying outcomes measurement and rating scales.Clinicians must realise that because this is an alien and somewhat ''dry'' area, they may need to invest some time to appreciate the issues.Instead of discussing specific scales or rating scales for rehabilitation, which will only be relevant to a limited audience, I have chosen to discuss the importance of rating scales and how to achieve high quality measurement.I hope this makes the text more widely applicable to the neurological community.The take home message is simple; neurologists need to take their rating scales very seriously. WHY ARE RATING SCALES IMPORTANT? cRating scales are important because they are a method of measurement.Measurement is important because inferences are based on it.1 For example, in clinical trials we measure variables (for example, disability), perform statistical tests on the numbers generated by scales, and base conclusions on the results.These conclusions influence patient care, prescribing, policy making, and the expenditure of public funds.Thus, the validity of inferences from clinical trials is directly dependent on the quality of the measurement instruments used.Some measurements are clear cut-for example, mortality rates.However, measurement becomes complex for more abstract, ill defined, ''soft'' outcomes such as patient's perspectives of the impact of disease and their quality of life.If we are serious about using these abstract variables to evaluate clinical practice we must be serious about our attempts to measure them as rigorously as possible.Consider clinical trials of interferons and glatiramer acetate in multiple sclerosis (MS).These trials have produced interesting results: an incontrovertible reduction in relapse rate and accumulation of magnetic resonance image (MRI) lesions over time, but a debatable reduction in the progression of physical disability.These findings have prompted major developments including: research to understand the seemingly complex relation between pathology and disability; calls for definitive studies that are free from pharmaceutical conflicts of interest; a controversial review by the National Institute for Clinical Excellence; and the UK risk sharing scheme for prescribing disease modifying therapies.Despite these major developments, few have questioned seriously how the choice of rating scale may have influenced this course of events.This is highly relevant because these major developments in MS are effectively based on the assumption that Kurtzke's expanded disability scale (EDSS), the rating scale used in most MS treatment trials, was considered adequate enough to handle the task of measuring disability and detecting clinically significant change when it occurs.Unfortunately, data concerning the measurement properties of the EDSS do not give us that confidence.First, the EDSS mixes the measurement of different health domains-that is, impairment in the early part of the scale, mobility in the mid range of the scale, and bulbar function in the upper part of the scale.As such, the EDSS is not a pure disability measure.While this may not seem such a big deal it is akin to having a scale that measures length at one end, weight in the middle, and volume at the end.Second, the EDSS generates ordinal scores rather than interval measures.More about that later.Third, the EDSS has been proven less able than other ''disability'' scales to differentiate between individuals at one point in time and detect change in disability over time.These facts undermine the validity of inferences made on the basis of the analysis of EDSS scores.Consequently, we are at risk of making inaccurate inferences about disability in MS every time we use the EDSS.The use of different statistical methods to analyse results acquired from rating scales cannot overcome flaws within the rating scale itself.
Author: J Hobart
Institution: Derriford Hospital
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: rating scales, outcome measurement, measurement validity, Expanded Disability Status Scale, multiple sclerosis, disability assessment, measurement properties, clinical trials, quality of life, patient-reported outcomes, measurement error, disease-modifying therapy, relapse rate, MRI lesion burden, risk-sharing schemes, National Institute for Clinical Excellence
Open Access status: bronze
OpenAlex ID: W2049600735
